<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447667</url>
  </required_header>
  <id_info>
    <org_study_id>MRE</org_study_id>
    <nct_id>NCT01447667</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)</brief_title>
  <acronym>MRE</acronym>
  <official_title>Magnetic Resonance Elastography Score Reflecting Hepatic Fibrosis as an Independent Predictor for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine:

        -  The efficacy of MRE score as a predictor of HCC recurrence within 2 years after RFA
           treatment

        -  The efficacy of each indicator (MRE score, non-invasive serum markers) compared to the
           gold-standard histology score predicting hepatic fibrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate whether MRE score reflecting hepatic fibrosis can predict the recurrence of HCC
      within 2 years after RFA treatment

        -  Local recurrence/intrahepatic distant recurrence

        -  Multivariable analysis including several related factors to find whether MRE score is an
           independent predictor of HCC recurrence even after adjusting other factors (etiology of
           liver disease, size of HCC, vessel invasion, HBsAg titer, etc.)

      To find the efficacy of each indicator (MRE score, non-invasive serum markers) compared to
      the gold-standard histology score predicting hepatic fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who experienced HCC recurrence after RFA</measure>
    <time_frame>within 2 years after RFA procedure</time_frame>
    <description>To see whether MRE score reflecting hepatic fibrosis predicts the recurrence of HCC within 2 years after RFA treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of each indicator of hepatic fibrosis compared to the gold-standard histology score</measure>
    <time_frame>2 years after RFA</time_frame>
    <description>To find efficacy of each indicator (MRE, noninvasive serum markers such as APRI, P2/MS) compared to the gold-standard histology score in predicting hepatic fibrosis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hepatic Fibrosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Magnetic resonance elastography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetic resonance elastography before radiofrequency ablation therapy will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic resonance elastography</intervention_name>
    <description>Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue</description>
    <arm_group_label>Magnetic resonance elastography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as single hypervascular hepatocellular carcinoma initially

          -  AJCC stage I HCC

          -  Child-Pugh class A

          -  Planning radiofrequency ablation for HCC

          -  Voluntary agreement for this study

        Exclusion Criteria:

          -  Decreased kidney function (GFR &lt; 70 mL/min/kg)

          -  Contraindication to MRI (pacemaker, defibrillator)

          -  Contrast media hypersensitivity

          -  Other primary malignancy

          -  Acute viral hepatitis

          -  Prior history of liver transplantation

          -  Thrombosis in splenic vein or portal vein

          -  Patients who were enrolled to other clinical trials within 4 weeks

          -  Other severe chronic disease or psychiatric disease

          -  Pregnant or milk-feeding women

          -  Patients with coagulopathy, high risk of bleeding for the liver biopsy

          -  Patients who disagree to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Hwan Yoon, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Hwan Yoon, M.D., Ph.D</last_name>
    <phone>+82-2072-2228</phone>
    <email>yoonjh@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-Hoon Lee, M.D.</last_name>
    <phone>+82-2072-2228</phone>
    <email>pindra@empal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Hwan Yoon, M.D, Ph.D.</last_name>
      <phone>+82-2072-2228</phone>
      <email>yoonjh@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Hwan Yoon</investigator_full_name>
    <investigator_title>Clinical professor, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Hepatic fibrosis</keyword>
  <keyword>Magnetic resonance elastography</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

